P4-mediated antibody therapy in an acute model of invasive pneumococcal disease

Journal of Infectious Diseases

Volumn 205, Issue 9, 2012, Pages 1399-1407

  Bangert, Mathieu ^a,c   Bricio Moreno, Laura ^c   Gore, Suzanna ^c   Rajam, Gowrisankar ^b   Ades, Edwin W ^b   Gordon, Stephen B ^a   Kadioglu, Aras ^c  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CD16 ANTIGEN; FC GAMMA RECEPTOR II; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN RECEPTOR; P4 PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEREMIA; BACTERIAL LOAD; CELL ACTIVATION; FEMALE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LOBAR PNEUMONIA; LYMPHOCYTE FUNCTION; MACROPHAGE; MOUSE; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; SEPTICEMIA; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE;

ACUTE DISEASE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; BACTEREMIA; CELL LINE; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MICE; PHAGOCYTES; PNEUMOCOCCAL INFECTIONS; SEPSIS;

EID: 84861551926     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis223     Document Type: Article

References (46)

1. Black RE, Cousens S, Johnson HL, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010; 375:1969-87.
2. Scott JA. The preventable burden of pneumococcal disease in the developing world. Vaccine 2007; 25:2398-405.
3. Gordon SB, Chaponda M, Walsh AL, et al. Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-term survival. AIDS 2002; 16:1409-17.
4. Mortensen EM, Restrepo MI, Anzueto A, Pugh JA. Antibiotic therapy and 48-hour mortality for patients with pneumonia. Am J Med 2006; 119:859-64.
5. Imran MN, Leng PH, Yang S, Kurup A, Eng P. Early predictors of mortality in pneumococcal bacteraemia. Ann Acad Med Singapore 2005; 34:426-31.
6. Tunkel AR. Adjunctive corticosteroids for adults in sub-Saharan Africa with bacterial meningitis. Curr Infect Dis Rep 2008; 10:290-1.
7. Schito GC, Debbia EA, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project. J Antimicrob Chemother 2000; 46(Suppl T1):3-9.
8. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Diagn Microbiol Infect Dis 1997; 29:249-57.
9. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41.
10. Ron D. Serotype replacement in perspective. Vaccine 2009; 27(Suppl 3): C22-C4.
11. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004; 2:695-703.
12. Rajam G, Sampson J, Carlone GM, Ades EW. An augmented passive immune therapy to treat fulminant bacterial infections. Recent Pat Antiinfect Drug Discov 2010; 5:157-67.
13. Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52:447-56.
14. Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 2010; 38:e66-73.
15. Rajam G, Anderton JM, Carlone GM, Sampson JS, Ades EW. Pneumococcal surface adhesin A (PsaA): a review. Crit Rev Microbiol 2008; 34:131-42.
16. Melnick N, Rajam G, Carlone GM, Sampson JS, Ades EW. Evaluation of a novel therapeutic approach to treating severe pneumococcal infection using a mouse model. Clin Vaccine Immunol 2009; 16:806-10.
17. Rajam G, Bangert M, Hammons GM, et al. P4 peptide therapy rescues aged mice from fatal pneumococcal sepsis. Clin Vaccine Immunol 2010; 17:1823-4.
18. Rajam G, Phillips DJ, White E, et al. A functional epitope of the pneumococcal surface adhesin A activates nasopharyngeal cells and increases bacterial internalization. Microb Pathog 2008; 44:186-96.
19. Weeks JN, Boyd KL, Rajam G, Ades EW, McCullers JA. Immunotherapy with a combination of intravenous immune globulin and p4 peptide rescues mice from postinfluenza pneumococcal pneumonia. Antimicrob Agents Chemother 2011; 55:2276-81.
20. Kadioglu A, De Filippo K, Bangert M, et al. The integrins Mac-1 and alpha4beta1 perform crucial roles in neutrophil and T cell recruitment to lungs during Streptococcus pneumoniae infection. J Immunol 2011; 186:5907-15.
21. Kadioglu A, Brewin H, Hartel T, et al. Pneumococcal protein PavA is important for nasopharyngeal carriage and development of sepsis. Mol Oral Microbiol 2010; 25:50-60.
22. Gingles NA, Alexander JE, Kadioglu A, et al. Role of genetic resistance in invasive pneumococcal infection: identification and study of susceptibility and resistance in inbred mouse strains. Infect Immun 2001; 69:426-34.
23. Kadioglu A, Gingles NA, Grattan K, Kerr A, Mitchell TJ, Andrew PW. Host cellular immune response to pneumococcal lung infection in mice. Infect Immun 2000; 68:492-501.
24. Kadioglu A, Coward W, Colston MJ, Hewitt CR, Andrew PW. CD4-Tlymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection. Infect Immun 2004; 72:2689-97.
25. Rajam G, Skinner J, Melnick N, et al. A 28-aa pneumococcal surface adhesin A-derived peptide, P4, augments passive immunotherapy and rescues mice from fatal pneumococcal infection. J Infect Dis 2009; 199:1233-8.
26. Romero-Steiner S, Frasch C, Concepcion N, et al. Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diagn Lab Immunol 2003; 10:1019-24.
27. Mikolajczyk MG, Concepcion NF, Wang T, et al. Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations. Clin Diagn Lab Immunol 2004; 11:1158-64.
28. Lam J, Herant M, Dembo M, Heinrich V. Baseline mechanical characterization of J774 macrophages. Biophys J 2009; 96:248-54.
29. van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004; 351:1849-59.
30. Gordon SB, Walsh AL, Chaponda M, et al. Bacterial meningitis in Malawian adults: pneumococcal disease is common, severe, and seasonal. Clin Infect Dis 2000; 31:53-7.
31. Koedel U, Klein M, Pfister HW. New understandings on the pathophysiology of bacterial meningitis. Curr Opin Infect Dis 2010; 23: 217-23.
32. Simell B, Vuorela A, Ekstrom N, et al. Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis. Vaccine 2011; 29:1929-34.
33. Krause I, Wu R, Sherer Y, Patanik M, Peter JB, Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparationsda potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med 2002; 12:133-9.
34. Hemming VG. Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin Diagn Lab Immunol 2001; 8:859-63.
35. Hong DK, Tremoulet AH, Burns JC, Lewis DB. Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza a virus in intravenous immunoglobulin preparations. Pediatr Infect Dis J 2011; 30:67-9.
36. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291: 484-6.
37. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26:513-33.
38. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313:670-3.
39. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 2008; 105:19571-8.
40. Kadioglu A, Andrew PW. Susceptibility and resistance to pneumococcal disease in mice. Brief Funct Genomic Proteomic 2005; 4:241-7.
41. Rodriguez A, Lisboa T, Blot S, et al. Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Med 2009; 35:430-8.
42. Craig A, Mai J, Cai S, Jeyaseelan S. Neutrophil recruitment to the lungs during bacterial pneumonia. Infect Immun 2009; 77:568-75.
43. Robbins CS, Swirski FK. The multiple roles of monocyte subsets in steady state and inflammation. Cell Mol Life Sci 2010; 67:2685-93.
44. Kamei M, Carman CV. New observations on the trafficking and diapedesis of monocytes. Curr Opin Hematol 2010; 17:43-52.
45. Swirski FK, Nahrendorf M, Etzrodt M, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009; 325:612-16.
46. Stuart LM, Ezekowitz RA. Phagocytosis: elegant complexity. Immunity 2005; 22:539-50.